key: cord-0995514-n311ptne
authors: Avanzato, Victoria A.; Matson, M. Jeremiah; Seifert, Stephanie N.; Pryce, Rhys; Williamson, Brandi N.; Anzick, Sarah L.; Barbian, Kent; Judson, Seth D.; Fischer, Elizabeth R.; Martens, Craig; Bowden, Thomas A.; de Wit, Emmie; Riedo, Francis X.; Munster, Vincent J.
title: Case Study: Prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised cancer patient.
date: 2020-11-04
journal: Cell
DOI: 10.1016/j.cell.2020.10.049
sha: 7b103b922043e1859f48d53e5bfc415be39b7e7e
doc_id: 995514
cord_uid: n311ptne

Long-term SARS-CoV-2 shedding was observed from the upper respiratory tract of a female immunocompromised patient with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Shedding of infectious SARS-CoV-2 was observed up to 70 days, and genomic and subgenomic RNA up to 105 days past initial diagnosis. The infection was not cleared after a first treatment with convalescent plasma, suggesting limited impact on SARS-CoV-2 in the upper respiratory tract within this patient. Several weeks after a second convalescent plasma transfusion, SARS-CoV-2 RNA was no longer detected. We observed marked within-host genomic evolution of SARS-CoV-2, with continuous turnover of dominant viral variants. However, replication kinetics in Vero E6 cells and primary human alveolar epithelial tissues were not affected. Our data indicate that certain immunocompromised patients may shed infectious virus for longer durations than previously recognized. Detection of subgenomic RNA is recommended in persistently SARS-CoV-2 positive individuals as a proxy for shedding of infectious virus.

CoV-2 shedding and transmission potential in both symptomatic and asymptomatic cases. 59 60 Estimates suggest that infectiousness begins 2.3 days prior to symptom onset and declines within 7 61 days of symptom onset (He et al., 2020b). Consistent with this, infectious SARS-CoV-2 has been 62 isolated from patient samples taken up to 8 days after symptom onset, but typically not thereafter 63 (Wolfel et al., 2020 , Bullard et al., 2020 . In contrast to the prolonged shedding of SARS-CoV-2 64 ( Figure 1 ). After the initial SARS-CoV-2 diagnosis, the patient was kept in isolation at an isolation 94 ward in a single room with negative airflow. Attending medical staff were using full personal 95 protective equipment comprised of Powered Air Purifying Respirators (PAPR) or N95 respirators 96 with goggles, gowns and gloves. Over the course of the next 15 weeks, she was tested for SARS-97

CoV-2 another 14 times by several diagnostic companies and remained positive on testing through 98 June 15, 2020, 105 days since the initial positive test. Subsequently, the patient tested negative on 99 four consecutive swabs from June 16 to July 16, indicating her infection had cleared. 100 101 Due to acquired hypogammaglobulinemia caused by her CLL, the patient received intravenous 102 immunoglobulin (IVIG) every 4 to 6 weeks as part of her treatment regimen. She received IVIG 103 treatment on both April 6 and May 6, 2020. The manufacture date of her specific lot of IVIG 104 preceded January 1, 2020, before the beginning of the COVID-19 pandemic and therefore did not 105 contribute to any SARS-CoV-2 serology results (Table S2 ). Due to the persistence of her SARS-106

CoV-2 infection, serum samples were tested for antibodies against the spike glycoprotein through 107 a study at the NIH Clinical Center and no spike-specific antibodies were detected (Burbelo et al., 108 2020 ). On May 12, 2020, she was transfused with 200 mL of SARS-CoV-2 convalescent plasma 109 provided by Bloodworks Northwest under an FDA eIND protocol with a virus neutralizing (VN) 110 titer of 60 (Table 1) . Her infection persisted, and on May 23, 2020, she received another 200 mL 111 dose of convalescent plasma from a different donor with a VN titer of 160 under the same protocol 112 (Table 1) . Additional laboratory values are available in Table S3 . 113 RNA (gRNA), subgenomic RNA (sgRNA) and infectious SARS-CoV-2. RNA was extracted from 117 nasopharyngeal and oropharyngeal swabs collected at 49, 70, 77, 85, 105, and 136 days from the 118 initial diagnosis and evaluated for the presence of viral gRNA (Corman et al., 2020) and sgRNA 119 (Wolfel et al., 2020) . gRNA and sgRNA were detected in nasopharyngeal swabs out to day 105, 120 except for the swab taken at day 77 (Figure 2A neutralizing antibodies in a virus neutralization (VN) assay ( Figure 2B and 2C, Figure S1A and 142 S1B, and Table 1 The second dose of convalescent plasma (convalescent plasma 2) had an IgG spike titer of 5120, 145 RBD titer of 5120 and a VN titer of 160 ( Figure 2B , S1A, Table 1 ). Prior to the first dose of 146 plasma given on day 71, detectable spike and RBD IgG antibody titers were very low in serum 147 collected from the patient, with IgG titers between 1:10 and 1:40 at day 49 and 71 pre transfusion; 148 no VN titers were detected in these samples. Immediately after the first transfusion at day 71, the 149 spike and RBD IgG antibody titers rose to 1:320 and then decreased to 1:80 and 1:160 respectively 150 at day 77. No VN titers were detected at day 71 and 77 ( Figure 2C , S1B, Table 1 ). Immediately 151 after the second transfusion at day 82 the spike and RBD IgG titers increased to 1:320 and 1:640 152 respectively and remained elevated by day 105 ( Figure 2C , S1B). Low neutralizing titers of 1:10 153 were observed at day 82 and 105 (Table 1) The phylogenetic trees show that the patient genomes in this study cluster as a monophyletic clade 200 consistent with infection in late February/early March followed by viral persistence ( Figure S2 ). 201 202 Next, full genome sequences from the two SARS-CoV-2 isolates were obtained (Table S4) CoV-2 isolates cultured from those swabs were compared to the reference strain USA/WA1/2020 205 directly from the patient swabs and the SARS-CoV-2 isolates. In addition, a 3 nt deletion leading 208 to the loss of a methionine residue was observed in nsp1 in day 49 and day 70 samples (Table 2) . 209

Within the genomes of the two SARS-CoV-2 isolates, two in-frame deletions were observed in the 210 spike glycoprotein coding region. A 21 nt in-frame deletion (residue 21,975 -21,995) was found 211 in the N-terminal domain (NTD) of S1, leading to a 7 amino acid deletion (aa 139-145) within the 212 spike glycoprotein of the SARS-CoV-2 day 49 isolate. A smaller 12 nt deletion (residues 21,982 -213 21,993) was detected in the day 70 isolate, leading to a 4 amino acid deletion (aa 141-144) in the 214 NTD, which falls within the 7-amino acid deletion found in the day 49 isolate ( Figure 5A ). These 215 observed deletions in the spike glycoprotein map to a region in the NTD that is partially solvent- We would like to thank Neeltje van Doremalen, Jonathan Schulz, Myndi Holbrook, Anita Mora 355 and Rose Perry for excellent technical assistance. We would like to thank MatTek corporation for 356 providing the alveolar tissue culture system and technical support, as well as all the originating and 357 submitting laboratories and authors who deposited SARS-CoV-2 genomes to GISAID. We would 358 also like to thank the health care workers and laboratorians at EvergreenHealth for the selfless 359 service to patients. Finally, to the patient described in this report for her gracious willingness to 360 participate and contribute to these studies as we sought to understand this enigmatic infection. reported as log 10 50% tissue culture infective dose (TCID 50 /mL). 1.5 x 10 4 Vero E6 cells were 546 seeded into each well in 96-well plates in DMEM supplemented with 10% fetal bovine serum, 1 547 mM L-glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin and incubated overnight at 548 37°C and 5% CO 2 . The following morning, when the cells were at approximately 90% 549 confluency, the wells were inoculated with ten-fold serial dilutions of virus stock diluted in virus 550 isolation medium (100 uL per well, with 10 replicate wells for each dilution). The plates were 551 incubated at 37°C and 5% CO 2, and the cytopathic effect (CPE) was assessed for each well after 552 5 days. Wells that demonstrated CPE were counted, and the titer was determined by the method 553 of Spearman and Kärber using 10 replicates as follows: 554

where X is log 10 of the lowest dilution with all wells positive for CPE, d is log 10 of the dilution 556 factor (10 in these titrations), and S is the sum of the fraction of wells positive for CPE at all 557 tested dilutions. Virus isolation of the clinical specimen was performed on Vero E6 cells in 96 well plates. In 577 brief, media was removed from wells and replaced with 100 µL of undiluted swab sample, or 578 swab sample diluted 1:10 in DMEM supplemented with 2% fetal bovine serum (Gibco), 1 mM 579 L-glutamine (Gibco), 50 U/mL penicillin and 50 µg/mL streptomycin (Gibco) (virus isolation 580 medium). Diluted and undiluted samples were inoculated onto 7 wells. Spin inoculation was 581 performed at 1000 x g for 1 hour at 35°C. Inoculum was removed and wells were washed twice 582 with and replaced with 100 µL of virus isolation medium and incubated at 37°C and 5% CO 2 . 583 inoculate T25 flasks of Vero E6 cells in virus isolation medium and incubated at 37°C and 5% 585 CO 2 . Flasks were observed for cytopathic effect. RNA was extracted, as described above, for 586 confirmation of SARS-CoV-2 by qRT-PCR and next generation sequencing. 587 588

Vero E6 cells were seeded in 6 well plates at a density of 4 x 10 5 cells/well in DMEM 590 supplemented with 2% fetal bovine serum (Gibco), 1 mM L-glutamine (Gibco), 50 U/mL 591 penicillin and 50 µg/mL streptomycin (Gibco) (virus isolation medium) and incubated overnight 592 at 37°C and 5% CO 2 . The following day, the media was removed from the wells and replaced 593 with 1 mL of virus isolation medium containing virus at a MOI of 0.01. The patient day49 isolate 594 and the USA/WA1/2020 strain were tested in triplicate, with mock control wells in triplicate. 595

After a 1-hour incubation at 37°C and 5% CO 2 , the inoculum was removed, and wells were 596 washed 3x with PBS and replaced with a fresh 2 mL of virus isolation medium. Supernatant 597 samples were taken at 0, 12, 24, 48, 72, 96, and 120 hours post inoculation. Titer of infectious 598 virus from supernatant was determined by endpoint titration in Vero E6 cells, as described 599

above, but using 4 replicates per sample to determine the TCID 50 /mL using the Spearman-Karber To process the ARTIC data a custom pipeline was developed. Fastq read pairs were first 700 compared to a database of ARTIC primer pairs to identify read pairs that had correct, matching 701 primers on each end. Once identified, the ARTIC primer sequence was trimmed off. Read pairs 702 that did not have the correct ARTIC primer pairs were discarded. Remaining read pairs were 703 collapsed into one sequence using AdapterRemoval (Schubert et Vero E6 cells cultured in DMEM supplemented with 10% fetal bovine serum, 1 mM L-757 glutamine, 50 U/mL penicillin and 50 µg/mL streptomycin were plated at 5 x 10 4 cells/well in 24 758 well plates containing Thermanox™ cover slips (Ted Pella, Redding, CA) for transmission 759 electron microscopy or silicon chips (Ted Pella, Redding, CA) for scanning electron microscopy 760 in the wells, and incubated overnight at 37°C and 5% CO 2 . The next day, media was carefully 761 aspirated from the wells and replaced with 1 mL of virus isolation medium containing SARS-762 CoV-2 virus at a MOI of 1 and incubated for 1 hour at 37°C and 5% CO 2 . Wells were washed 763 three times with PBS, then replaced with 1 ml fresh virus isolation medium and incubated at 764 37°C and 5% CO 2 . At 24 and 48 hours post-infection, wells were washed three times with PBS, 765 then fixed as described below. 766 the location of the observed deletions onto a SARS-CoV-2 spike structure (PDB: 6ZGE) 791 (Wrobel et al., 2020). Nucleotide sequence alignments were generated using MAAFT align 792 Standley, 2013, Katoh et al., 2002) implemented in Geneious Prime v.2020.1.2 793 (https://www.geneious.com) and amino acid sequence alignments were generated with Multalin 794 (Corpet, 1988) replicates. The statistical analysis was performed using a 2-way ANOVA in Graphpad Prism 804 8.2.0. Further methods to determine whether the data met assumptions of the statistical approach 805

were not relevant for these analyses. 806 F., HOHLOCH, K., DROOGENDIJK, J., VAN DER KLIFT, M., VAN DER SPEK, E., ILLMER, T.,

CLL and COVID-19 at the Hospital Clinic of 821 Barcelona: an interim report

Covid-19 in Critically Ill 825 Patients in the Seattle Region -Case Series

Potent neutralizing 832 antibodies from COVID-19 patients define multiple targets of vulnerability

Predicting infectious SARS-CoV-2 from diagnostic samples

Detection of Nucleocapsid Antibody to SARS-CoV-2 is 839

More Sensitive than Antibody to Spike Protein in COVID-19 Patients. medRxiv

Molecular characterization of SARS-CoV-2 from the first case of COVID-19 in Italy

Duration of Isolation and Precautions for Adults with COVID-19

People with Certain Medical Conditions

A neutralizing human antibody binds to the N-terminal domain of 850 the Spike protein of SARS-CoV-2

Detection of 855 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Multiple sequence alignment with hierarchical clustering

The clinical observation of a 859 patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. ModelFinder: fast model selection for accurate phylogenetic estimates

MAFFT: a novel method for rapid multiple 914 sequence alignment based on fast Fourier transform

MAFFT multiple sequence alignment software version 7: 916 improvements in performance and usability

The Architecture of SARS-CoV

Atypical presentations of MERS-CoV infection in immunocompromised hosts

Influenza in immunosuppressed populations: a review of 924 infection frequency, morbidity, mortality, and vaccine responses

Positive RT-PCR Test Results in Patients 927 Recovered From COVID-19

Fast gapped-read alignment with Bowtie 2

Attenuated SARS-CoV-2 932 variants with deletions at the S1/S2 junction

Clinical Course and Molecular Viral Shedding Among 935

Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment 936 Center in the Republic of Korea

The Sequence Alignment/Map 939 format and SAMtools

Case Report: Viral Shedding for 60 Days in a Woman with 941 COVID-19

Prolonged virus shedding even after seroconversion in a patient with COVID-19

A severe-type COVID-19 case with prolonged virus shedding

COVID-19) Patients with Convalescent Plasma

AdapterRemoval v2: rapid adapter trimming, 1010 identification, and read merging

Genomic 1013 Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients With Coronavirus 1014 Disease

GISAID: Global initiative on sharing all influenza data -from vision to 1016 reality

Two X-linked agammaglobulinemia patients develop 1019 pneumonia as COVID-19 manifestation but recover

SARS-CoV-2 infection dynamics in lungs of African 1023 green monkeys

CoV-2 RNA in Body Fluids

Prolonged influenza virus shedding and emergence of 1030 antiviral resistance in immunocompromised patients and ferrets

Shedding of infectious virus in hospitalized patients with coronavirus disease-1037 2019 (COVID-19): duration and key determinants. medRxiv

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Detection of SARS-CoV-2 in 1041

Different Types of Clinical Specimens

Coronaviruses: An Updated Overview of Their Replication and 1043

Coronaviruses. Methods in Molecular Biology. NY: 1044 Humana

Virological assessment 1048 of hospitalized patients with COVID-2019

SARS-CoV-2 Viral Load in Upper In Brief: This case study describes a female immunocompromised patient with chronic lymphocytic leukemia and acquired hypogammaglobulinemia who became persistently infected with SARS-CoV-2. Though asymptomatic throughout the course of infection, the patient demonstrated prolonged shedding of both infectious SARS-CoV-2 virus and RNA. This study demonstrates certain patients may remain infectious for prolonged periods of time and highlights the need for further studies to understand risk factors for prolonged infectious SARS-CoV-2 shedding. Highlights: • Persistent SARS-CoV-2 infection and shedding in immunocompromised patient • Infectious SARS-CoV-2 isolated up to 70 days post diagnosis • Observed within-host genetic variation

Cells were fixed with Karnovsky's formulation of 2% paraformaldehyde/2.5% glutaraldehyde in 769 0.1 M Sorenson's phosphate buffer, and then post-fixed with 1.0% osmium tetroxide/0.